CPT Codes

caMRSA

This algorithm is for community associated MRSA (Methicillin-resistant Staphylococcus aureus, read more at http://en.wikipedia.org/wiki/MRSA). Note this algorithm will use lab results and not ICD-9 codes, as ICD-9 codes are not specific enough for this algorithm and/or are not used consistently for this phenotype. Thus, we expect the actual number of cases to be higher than what the eMERGE RC (Record Counter) estimated, and, as we will be studying patients aged 0 to 89, we would like for all sites to participate, please...

Owner Phenotyping Groups:

eMERGE Northwestern Group

View Phenotyping Groups:

eMERGE Phenotype WG

Final

Cardiac Conduction (QRS)

Algorithm to select subjects with "normal" electrocardiograms. Subjects do not have heart disease, interfering medications, or abnormal electrolytes at the time of the normal ECG. Individuals may, however, develop abnormalities later in life.

Hypothetical timeline for a single patient:

Owner Phenotyping Groups:

eMERGE Vanderbilt Group

View Phenotyping Groups:

eMERGE Phenotype WG

Final

Cardiorespiratory Fitness Algorithm (eMERGE Mayo Network Phenotype)

Please refer to attached documents.

Owner Phenotyping Groups:

eMERGE Columbia Group

eMERGE Mayo Group

View Phenotyping Groups:

eMERGE Phenotype WG

Final

Cataracts

We used a multi-modal strategy consisting of structured database querying, natural language processing on free-text documents, and optical character recognition on scanned clinical images to identify cataract subjects and related cataract attributes.

Owner Phenotyping Groups:

eMERGE Marshfield Group

View Phenotyping Groups:

eMERGE Phenotype WG

Final

Chronic Kidney Disease

Chronic kidney disease (CKD) is defined as an abnormality of kidney structure or function present for longer than 3 months. CKD can occur as a result of heterogeneous disorders affecting the kidney. In the United States, an estimated 13.6% of adults have CKD. Notably, adjusted mortality rates are higher for patients with CKD than those without, and rates increase with CKD stage. The purpose of this algorithm is to enable accurate CKD diagnosis and staging based on EHR data.

Owner Phenotyping Groups:

eMERGE Columbia Group

View Phenotyping Groups:

001

American-Swiss Allergy Phenotyping Group

BioVU Phenotyping

Clostridium Difficile Colitis Phenotype Group

Data Science to Patient Value Initiative (D2V) - Colorado

Denny’s Group at Vandy

eMERGE CCHMC Group

eMERGE CCHMC/BCH Group

eMERGE CHOP Group

eMERGE Columbia Group

eMERGE Geisinger Group

eMERGE GHC/University of Washington Group

eMERGE Harvard Group

eMERGE Marshfield Group

eMERGE Mayo Group

eMERGE Meharry Group

eMERGE Mount Sinai Group

eMERGE Northwestern Group

eMERGE Phenotype WG

eMERGE Vanderbilt Group

Farr Institute Kidney Working Group

GPC

NIH Collaboratory Group

PCORI CDRN/PPRN

PCORI MidSouth CDRN

PCORI MidSouth CDRN/Duke Group

PCORI MidSouth CDRN/Greenway Group

PCORI MidSouth CDRN/HSSC Group

PCORI MidSouth CDRN/Meharry Group

PCORI MidSouth CDRN/UNC Group

PCORI MidSouth CDRN/VUMC Group

Precision Medicine and Health Disparities Collaborative

Resistant hypertension WG

Vanderbilt - Music Cognition Lab

Vanderbilt - SD/RD Group

VESPA - Vanderbilt Electronic Systems for Pharmacogenomic Assessment

Final

Clopidogrel Poor Metabolizers

Note: Attached documents contain full case definition and two different control definitions. One is for controls with 2 years of follow up, the other for controls with 1 year of follow up. All available controls with 2 years of follow up were used in Vanderbilt's study. The control population was supplemented by controls with only 1 year of follow up. At the time of study, many of the available controls had experienced their qualifying events somewhat recently and 2 years had not yet passed for full follow up.

Owner Phenotyping Groups:

VESPA - Vanderbilt Electronic Systems for Pharmacogenomic Assessment

View Phenotyping Groups:

Denny’s Group at Vandy

VESPA - Vanderbilt Electronic Systems for Pharmacogenomic Assessment

Final

Colorectal Cancer (CRC)

A pheontype defining patients with strong evidence of having been diagnosed with colorectal cancer (cases) and patients who clearly do not have such diagnoses (controls). This phenotype is being used for sequencing studies. The only NLP involved in this phenotype is a very simple string search applied to pathology reports.

Owner Phenotyping Groups:

eMERGE GHC/University of Washington Group

Final

Consistent Care

Owner Phenotyping Groups:

eMERGE Harvard Group

View Phenotyping Groups:

eMERGE Phenotype WG

Final

CRS (Chronic Rhinosinusitis)

Please see the PubMed reference below for background information about this phenotype & algorithm (a copy also attached).

Owner Phenotyping Groups:

eMERGE Geisinger Group

eMERGE Northwestern Group

eMERGE Phenotype WG

View Phenotyping Groups:

eMERGE Geisinger Group

eMERGE Northwestern Group

eMERGE Phenotype WG

Final

Depression

Depression accounts for substantial morbidity and mortality worldwide and risk of experiencing it may have a genetic component. Depressive disorders manifest along a gradient from mild to severe.[1] Electronic health record (EHR) data linked to large, multi-site biobanks[2] facilitate exploration of the genetic component of depression.

Owner Phenotyping Groups:

eMERGE GHC/University of Washington Group

View Phenotyping Groups:

eMERGE Phenotype WG

Final

Search form

Pages